Here are the 424B prospectus supplements from Sangamo Therapeutics Inc (SGMO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow SGMO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SGMO filings page.
Sangamo Therapeutics is offering 35,190,292 shares of common stock, pre-funded warrants for 17,787,033 shares, and purchase warrants for 52,977,325 shares. Securities are priced at $0.4719 per share and accompanying purchase warrant (or $0.4619 for a pre-funded warrant plus purchase warrant), yielding gross proceeds of about $24.8 million and estimated net proceeds of about $22.9 million before any warrant exercises.
The company plans to use the cash for working capital and general corporate purposes. Sangamo estimates cash and cash equivalents of approximately $20.9 million as of December 31, 2025 and, together with $2.0 million from its at-the-market program and this offering, expects funding only into the beginning of the third quarter of 2026.
The filing states there is substantial doubt about Sangamo’s ability to continue as a going concern even after this raise and notes active consideration of significant cost cuts and potential bankruptcy protection if additional capital or partnerships are not secured. The company also faces Nasdaq delisting risk due to its share price remaining below the $1.00 minimum bid requirement, with an extension to regain compliance by April 27, 2026.